Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.39 |
| ▸ | CBX7 | O95931 | 1/20 | 0.38 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6278606 | 0.87 | BCHE (0.42) | AVPR1ABCHETACR1NR4A1NR4A2 | |
| SCHEMBL6282932 | 0.84 | CDYL (0.42) | AVPR1ACNR2BCHETACR1MEN1 | |
| SCHEMBL6287758 | 0.84 | BCHE (0.40) | AVPR1ACNR2BCHETACR1NR4A1 | |
| SCHEMBL6287731 | 0.81 | FNTA (0.44) | BCHEKDM4E | |
| SCHEMBL6284730 | 0.81 | BCHE (0.45) | AVPR1ACNR2BCHETACR1NR4A1 | |
| SCHEMBL6285219 | 0.80 | FNTA (0.50) | AVPR1ATACR1DRD4MEN1KMT2A | |
| SCHEMBL6285454 | 0.80 | CNR2 (0.45) | AVPR1ACNR2TACR1MEN1KMT2A | |
| SCHEMBL6283118 | 0.79 | NPC1 (0.49) | BCHEDRD4CBX7CDY1; CDY1BGPR52 | |
| SCHEMBL6282969 | 0.77 | CNR2 (0.49) | CNR2BCHETACR1DRD4MEN1 | |
| SCHEMBL6285484 | 0.77 | FNTA (0.47) | CNR2TACR1DRD4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919365-B2 | Imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-19 | — | — | US | disclosed |
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1384715-A1 | NOVEL IMIDAZOLIDINEDIONE DERIVATIVES AND USE THEREOF AS DRUGS | Senju Pharmaceutical Co., Ltd. (JP) | 2004-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110811-A1 | Novel imidazolidinedione derivatives and use thereof as drugs | CMA1, TPSD1, TPSB2 | AVPR1A 3218/4885CNR2 650/4885BCHE 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.